Last Updated: September 21, 2026
Adding a second 340B pharmacy looks like simple growth on paper. In practice, it is a working-capital event: money leaves on one schedule and returns on another. At The Marketing Lab, we run 340B programs and contract pharmacy transitions, and in our experience, the clinical case for a second pharmacy is often straightforward, but the cash flow implications can be challenging.
The trap has three parts: the incumbent holds trailing receivables that belong to the clinic; a new pharmacy needs volume before it produces usable margin; and in a physical-inventory model, the clinic may fund roughly one month of drug cost before remittance catches up.
A 340B contract pharmacy transition plan is a written sequence of notice, registration, ramp, and reconciliation steps that moves volume without leaving the clinic short of cash. Model it month by month before anything is signed, in a spreadsheet the finance lead owns.
The plan has five moving parts, and they have to be sequenced:
Start with the contract, not the calendar. Most pharmacy services agreements include a 60-day no-cause termination provision and no exclusivity clause, because patient choice governs where a prescription is filled. The clinic cannot force volume to a new pharmacy, so the ramp depends on patient and prescriber behavior.
Before serving notice, confirm four things:
Registration comes next, and it is not instant. The new contract pharmacy must be added in 340B OPAIS and reflected in the covered entity's contract pharmacy arrangements before the first claim is submitted. HRSA publishes the requirements for contract pharmacy registration and recertification through its 340B Office of Pharmacy Affairs guidance.
A workable sequence looks like this:
| Month | Volume to New Pharmacy | Incumbent A/R Collected | New-Pharmacy Remittance | Withhold Released | Net Cash Position |
|---|---|---|---|---|---|
| Month 0 | 0% | Baseline | $0 | Held | Baseline |
| Month 1 | 50% | Partial | Partial | Requested | Watch closely |
| Month 2 | 75% | Partial | Partial | Installment 1 | Tightest point |
| Month 3 | 90% | Most collected | Most received | Installment 2 | Recovering |
| Month 4 | 100% | Cleared | Current | Balance | Normal |
This is the modeling RxLeverage does before a transition is signed. In programs we run, this modeling helps turn a potential two-pharmacy funding crunch into a scheduled, funded ramp.
340B cash flow modeling means reading the TPA statement on both a cash and an accrual basis, because the two tell different stories about the same month. Most programs skip this step, and it is the one that prevents surprises.
The disagreement is structural, not an error: cash-basis statements record what moved, accrual records what was earned. A "cash start-up" advance paid at a fixed percentage of charges creates a liability that only flips once the underlying A/R collects.
Physical-inventory models create a predictable cash dip because the clinic pays the wholesaler on one clock and gets paid on another. If the clinic funds drug purchases at roughly 30 days while remittance arrives at 45 to 60 days, it carries the cost of dispensed drugs for two to four weeks. Volume peaks in the fall, so the gap is widest exactly when the clinic can least afford it.
The mechanism, which most guides skip:
The fix is contractual, not operational, and it works best when several levers are pulled together:
Use this structure to forecast the transition. The numbers are the clinic's own; the columns are the point.
| Month | New-Pharmacy Volume | Wholesaler Payment Due | Remittance Received | Net Cash Position |
|---|---|---|---|---|
| Month 1 | 50% | Partial | Partial | Watch closely |
| Month 2 | 75% | Full | Partial | Tightest point |
| Month 3 | 90% | Full | Most received | Recovering |
| Month 4 | 100% | Full | Current | Normal |
Liquidity during a transition comes down to five levers, which work best together:
Compliance details decide whether the transition is financially clean. Two areas cause most of the damage.
The challenge with adding a second 340B pharmacy is not clinical or regulatory. It is surviving the two months when the clinic funds two pharmacies at once.
Book a free 30-minute strategy call.
Model the transition month by month before signing anything. Read the incumbent's statements on both cash and accrual bases, because a cash-basis cumulative ledger can show you owing the pharmacy while accrual shows the pharmacy holding your margin in trailing insurer A/R. Stage the ramp at roughly 50%, then 75, 90 and 100 percent, and confirm the new pharmacy's payment terms in writing. In our experience, the entities that get hurt are the ones that signed first and modeled after.
Most pharmacy services agreements state that patients choose their pharmacy and the contract is not exclusive. Practically, that means you can give notice and move volume without breaching the agreement. Check the notice period before you commit to a start date with the new pharmacy. In our experience, 60-day no-cause termination is common, and the sequencing rule is to reduce volume first, let A/R collect, request a true-up of the withhold reserve, then give notice.
Pharmacy agreements often hold back a percentage of remittances as a reserve against future reconciliation or audit adjustments. The reserve is typically releasable on request and reconciled quarterly, so ask for the current balance and a release schedule before you terminate. Requesting release in installments rather than a lump sum gives the pharmacy time to process and keeps your transition month from depending on a single payment landing on time.
In a physical-inventory model the clinic funds roughly one month of drug acquisition cost, paying the wholesaler at around 30 days while insurer remittance arrives at 45 to 60 days. That gap lands hardest in a high-volume month like November or December. Virtual or replenishment models avoid it because the pharmacy fronts the wholesaler purchases and remits on adjudicated claims. Ask which model you are signing before you sign it.
Reconcile at the claim level, not the statement total. Match each remittance to the adjudicated claim, the drug acquisition cost and the dispensing fee, then review net-per-claim by drug class. Non-HIV generics often run negative and should be carved out or moved to a different program modality. Run this monthly, and keep the reconciliation file with your audit documentation, because HRSA expects the entity to be able to explain its contract pharmacy economics.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
